Hepatitis B vaccine recombinant - Merck

Drug Profile

Hepatitis B vaccine recombinant - Merck

Alternative Names: HBvaxPRO; Hepatitis B vaccine (rDNA) - Merck

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur MSD
  • Developer Merck & Co; sanofi pasteur MSD
  • Class DNA vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B

Most Recent Events

  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 01 Feb 2015 Sanofi Pasteur MSD completes a phase III trial in Hepatitis B in Italy (NCT02012998)
  • 31 Dec 2001 Launched for Hepatitis B in Argentina (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top